Pfizer Inc. announced positive top-line results from a phase 3 study (B74710126) describing the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech Covid-19 vaccine or when each vaccine was given with placebo. Responses elicited by Prevnar 20 for all 20 serotypes were similar whether given with a dose of the Pfizer-BioNTech Covid-19 vaccine (n=190) or with placebo (n=191). Responses to a booster dose of the Pfizer-BioNTech Covid-19 vaccine were also similar when given with Prevnar 20 or given with placebo (n=189). The safety profile of co-administering Prevnar 20 with a booster dose of the Pfizer-BioNTech Covid-19 vaccine generally reflected that observed with the Pfizer-BioNTech Covid-19 vaccine booster dose.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!